Table 2 The characteristics of the cohort (IQR = interquartile range)
Total number of patients | 5 197 | |
|---|---|---|
Patient months | Overall On ART | 136 672 116 306 (85%) |
Duration on ART (months) | Median IQR | 19 (10 to 32) |
Age at starting ART (years) | Median IQR | 37.3 years (32.4 to 42.9) |
Sex | Female Male | 6 379(59.%) 4 356 (41%) |
Patient status at end of study period | Active Left the scheme Dead | 2 922 (56%) 1 834 (34%) 421 (8%) |
Baseline CD4+ cell count | Median IQR | 87 cells/μL (37 to 145) |
Baseline viral load (log10) | Median IQR | 5.22 (4.73 to 5.63) |
NNRTI used in first line | Nevirapine Efavirenz | 2 655 (26%) 6 711 (74%) |
NRTI combination in first line | Zidovudine + lamivudine Stavudine + lamivudineother other | 3 339 (65%) 1 225 (24%) 633 (11%) |
Duration of CD4+ cell count monitoring before starting ART (months) | Median IQR | 1.2 (0.6 to 2.6) |
Overall Adherence as measured by monthly pharmacy refill data | Median IQR | 74.4% (38.4 to 92.3) |